- Home
- PACB
as 11-07-2024 3:36pm EST
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | MENLO PARK |
| Market Cap: | 452.1M | IPO Year: | 2010 |
| Target Price: | $3.79 | AVG Volume (30 days): | 9.3M |
| Analyst Decision: | Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.16 - $10.65 | Next Earning Date: | 11-07-2024 |
| Revenue: | $188,871,000 | Revenue Growth: | 29.24% |
| Revenue Growth (this year): | -15.3% | Revenue Growth (next year): | 27.48% |
Stock Insider Trading Activity of Pacific Biosciences of California Inc. (PACB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kim Susan G. | PACB | See Remarks | Sep 30 '24 | Sell | $1.72 | 19,782 | $34,064.60 | 695,654 | |
| HENRY CHRISTIAN O | PACB | See Remarks | Sep 16 '24 | Sell | $1.75 | 98,907 | $172,691.62 | 2,497,763 | |
| Eidel Jeff | PACB | See Remarks | Aug 19 '24 | Sell | $1.59 | 26,760 | $42,601.92 | 869,730 | |
| Van Oene Mark | PACB | See Remarks | Aug 16 '24 | Sell | $1.66 | 38,011 | $63,174.28 | 1,630,815 |
Latest Pacific Biosciences of California Inc. News
PACB Breaking Stock News: Dive into PACB Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 hours ago
PacBio Announces Third Quarter 2024 Financial Results
GlobeNewswire
10 hours ago
PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028
GlobeNewswire
a day ago
PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop
GuruFocus.com
2 days ago
Pacific Biosciences of California Inc (PACB) Q3 2024 Earnings Report Preview: What To Expect
Zacks
4 days ago
Curious about Pacific Biosciences (PACB) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Zacks
7 days ago
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors
Insider Monkey
9 days ago
Pacific Biosciences (PACB): Promising Gene Editing Stock With Innovating Technology
PR Newswire
9 days ago
Volta Labs joins PacBio Compatible program to help PacBio customers scale sequencing through automated library prep
Compare PACB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PACB Pacific Biosciences of California Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.